Ayurvedic drug shows promising results in clinical trials

Astha-15 may be the first Ayurvedic drug in the global market addressing the respiratory disorders associated with the deadly Covid-19.

The Dalmia Healthcare is set to announce the launch of Astha-15, a polyherbal combination of 15 herbs developed by its research arm Dalmia Centre for Research and Development, for treatment of mild and moderate Covid patients.

“This is a proud moment for India, our own indigenous Ayurveda and Dalmia Healthcare Limited –has developed Astha-15 for the effective treatment of respiratory disorders in Covid patients. “We’re happy to announce that the outcome of the clinical trial showed that Astha-15 has significantly reduced the cough and wheezing, improved the respiratory rate and aid in the speedy recovery of Covid-19 patients with the improvement of quality of life during the treatment cycle,” said Sanjay Dalmia, Chairman, Dalmia Group of Companies.

Astha-15 will be made available in the first phase through prescriptions written for mild and moderate Covid patients undergoing treatment in Covid Hospitals. Dalmia Healthcare will be applying for permission/approval of Astha-15 usage in allopathic hospitals, as per the procedure in each hospital, he said.

Aptly named Astha or faith, Astha-15 acts as a bronchodilator, decongestant, anti-inflammatory and lung detoxifier. It helps in eliminating the infection and regulating the allergic reactions. This has a specific action on the mucosa of the respiratory tract and the muscular walls of the lungs that act as the airways. It has an anti-inflammatory effect which reduces inflammation and congestion inside the lungs. Its continuous use reduces the damage on the lungs and the muscular walls and brings out a significant reversal in their dysfunction. All these disorders which have been found in Covid-19 patients have been confirmed to be treated by Astha-15.

Dalmia Healthcare had earlier sought approval for Astha-15 by conducting a clinical trial to evaluate the efficacy and safety of poly-herbal combination for the treatment of Covid-19 along with standard care approved as per AYUSH/ICMR guidelines. After two successful phases, Phase III trial was conducted on 120 subjects at multi-centric sites viz. JNUIMSRC, Jaipur, Govt. Medical College & Govt. General hospital, Srikakulam (Old RIMSGGH) and RGMC & CSMH, Thane by following the regulatory guidelines of AYUSH and the Informed Consent Declaration, Insurance Terms and Hospital Ethics Committee approvals which are registered at DCGI to perform the clinical trial.

Managed by ayurvedamagazine.org

Leave a Comment: